Traditionally clinical trial outcomes are recorded as single reports (often with handcrafted
Narrative descriptions) at face-to-face research clinic visits. Typically, original medical records are gathered, copied and couriered to a trial coordinating centre, and then verified by trial clinicians according to pre-specified rules. The process is inefficient, expensive, and prone to errors.
We are looking back into previous trial datasets linked to other routinely collected medical data, acquired during people’s usual care, to identify more streamlined, and potentially more reliable methods to cost-effectively collect information for trials with fewer steps, with a particular focus on vascular outcomes and bleeding outcomes.
We are also developing methods to rapidly ascertain outcomes relevant to Covid-19 trials using the RECOVERY trial platform, which has recruited and started following about 40,000 participants in the UK since the beginning of the Covid-19 pandemic: https://www.recoverytrial.net/
EMPA-KIDNEY trial: Effect of empagliflozin on chronic kidney disease progression
7 December 2022
EMPA-KIDNEY is an international clinical trial by Oxford Population Health scientists in collaboration with academics spanning eight countries. The study recruited over 6000 participants to...
Data experts call for better use of routine health data in clinical trials
20 July 2022
In a commentary published today, HDR UK researchers describe how a key roadblock to using the UK’s rich resources of health data can be removed to make clinical trials faster and more efficient.
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
21 June 2022
A large-scale clinical trial of a monoclonal antibody treatment for COVID-19 showed that it could reduce deaths by 21 per cent in people who had not mounted a natural antibody response of their own.